News

Learn more about our latest achievements, product updates, and our involvement in research projects

mHealth solution aims to reduce hospital readmissions
Bettina van Wylich-Muxoll

mHealth solution aims to reduce hospital readmissions

Copenhagen, Denmark – 9 February 2016. Monsenso ApS, a Copenhagen-based technology company, has been granted 3.065 million DKK by the Innovation Fund to develop further develop their mHealth solution that aims to reduce hospital readmissions of patients with depression and bipolar disorder.

The RADMIS research project, which has been granted a budget of 10.1 million DKK by the Innovation Fund, is being done in collaboration with the Mental Health Services of the Capital Region of Denmark (RHP) and the Danish Technical University (DTU).

Depression and bipolar disorder are the leading cause of disability worldwide, imposing a very high burden for society in terms of cost, lost productivity, and mortality. Besides, patients with affective disorders are hospitalized more frequently than any other patient group. The treatment of depression and bipolar disorder includes medication, psycho-education, and Cognitive Behavioral Therapy (CBT).

The RADMIS research project aims to establish clinical evidence that the Monsenso mHealth solution can reduce the number of hospital readmissions of patients with depression and bipolar disorder. It also seeks to decrease the symptoms and improve the quality of life of outpatients with depression or bipolar disorder receiving smartphone-based CBT.

Since smartphones are equipped with powerful sensing, computation and communication capabilities, they provide a unique platform to monitor and treat patients with depression and bipolar disorder. Moreover, smartphones also provide a rich multi-media and communication platform for Ecological Momentary Intervention (EMI) enabling patients to receive context-aware treatment in real-time, including medication reminders and CBT.

The innovation goals of the RADMIS research project are to:

  1. Research, design, and develop an intelligent smartphone-based monitoring and treatment platform for affective disorders
  2. Provide clinical evidence to reduce the number and duration of hospital re-admissions of patients with depression and bipolar disorder using smartphone-based treatment
  3. Provide clinical evidence that smartphone-based CBT improves the health outcomes for patients with depression and bipolar disorder

With regards to the new capabilities that will be added to the Monsenso mHealth solution, Thomas Lethenborg, CEO at Monsenso commented, “This intelligent smartphone-based monitoring and treatment platform for depression and bipolar disorders is the first of its kind; there are no similar solutions available on the market.”

“Once the clinical trial is completed, we will have the necessary evidence to prove that smartphone-based CBT helps reduce hospital readmissions of psychiatric patients. Besides, it allows health care systems to reach out to the 75% of the population in Europe who need treatment, but remain untreated,” added Mr. Lethenborg.

For additional information contact:
Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 71 7713
highland@monsenso.comYou can download this article as PDF in English and Danish